$49.61
-0.16 (-0.32%)
Open$50.15
Previous Close$49.77
Day High$50.41
Day Low$48.55
52W High$240.00
52W Low$7.00
Volume—
Avg Volume37.4K
Market Cap136.98M
P/E Ratio—
EPS$-38.31
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
-9.7% upside
Current
$49.61
$49.61
Target
$44.79
$44.79
$31.89
$44.79 avg
$48.55
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.25M | 53.02M | 47.19M |
| Net Income | -110,695,812 | 1.91M | 1.39M |
| Profit Margin | -1,079.9% | 3.6% | 2.9% |
| EBITDA | -109,958,977 | 2.67M | 2.51M |
| Free Cash Flow | — | 1.24M | 802.3K |
| Rev Growth | — | +15.8% | -2.9% |
| Debt/Equity | 0.06 | 0.46 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |